Taysha Gene Therapies Reports Q3 2026 Results; Cash of $422.8 Million

Taysha Gene Therapies reported a third-quarter 2026 net loss of $39.1 million, compared with $32.7 million a year earlier, and ended September with $422.8 million in cash and cash equivalents. The company said its TSHA-102 Rett syndrome trials are ongoing and expects to report six-month interim dat…